High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy

Evan J. Anderson, Judith Guzman-Cottrill, Morris Kletzel, Kimberly Thormann, Christine Sullivan, Xiaotian Zheng, Ben Z. Katz

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

ADV has emerged as an important pathogen in children undergoing allogeneic HPCT. A prospective study of the epidemiology of ADV infection and preemptive therapy of high risk ADV infections in children undergoing HPCT was undertaken. Cultures of throat, urine, and stool for viral pathogens and plasma for ADV PCR were obtained prior to transplantation, weekly for the first 100 days, and then monthly for one yr. Children developing high-risk ADV infections were treated preemptively with cidofovir 1 mg/kg/day given three times weekly for three wk. A case-controlled study was performed to identify risk factors for high-risk ADV infections. Seven (18%) of the 38 subjects developed high-risk ADV infections usually within 100 days of HPCT and were preemptively treated with i.v. cidofovir at a dose of 1 mg/kg/dose three times weekly for nine doses. High-risk ADV infections resolved in all seven patients without renal toxicity. CMV viremia occurred in two of seven patients during or shortly after therapy with cidofovir. A case-control study did not identify any risk factors that achieved statistical significance. Treatment with a modified dosing regimen of cidofovir was well-tolerated and high-risk ADV infections resolved in all patients.

Original languageEnglish (US)
Pages (from-to)219-227
Number of pages9
JournalPediatric Transplantation
Volume12
Issue number2
DOIs
StatePublished - Mar 2008

Fingerprint

Hematopoietic Stem Cells
Adenoviridae
Pediatrics
Transplants
Infection
Therapeutics
Viremia
Pharynx
cidofovir
Transplant Recipients
Case-Control Studies
Epidemiology
Transplantation
Urine
Prospective Studies
Kidney
Polymerase Chain Reaction

Keywords

  • Adenovirus
  • Cidofovir
  • Hematopoietic progenitor cell transplantation
  • Infection
  • Treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. / Anderson, Evan J.; Guzman-Cottrill, Judith; Kletzel, Morris; Thormann, Kimberly; Sullivan, Christine; Zheng, Xiaotian; Katz, Ben Z.

In: Pediatric Transplantation, Vol. 12, No. 2, 03.2008, p. 219-227.

Research output: Contribution to journalArticle

Anderson, Evan J. ; Guzman-Cottrill, Judith ; Kletzel, Morris ; Thormann, Kimberly ; Sullivan, Christine ; Zheng, Xiaotian ; Katz, Ben Z. / High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. In: Pediatric Transplantation. 2008 ; Vol. 12, No. 2. pp. 219-227.
@article{e3fe4c071ae4405c81b8febfe46a6221,
title = "High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy",
abstract = "ADV has emerged as an important pathogen in children undergoing allogeneic HPCT. A prospective study of the epidemiology of ADV infection and preemptive therapy of high risk ADV infections in children undergoing HPCT was undertaken. Cultures of throat, urine, and stool for viral pathogens and plasma for ADV PCR were obtained prior to transplantation, weekly for the first 100 days, and then monthly for one yr. Children developing high-risk ADV infections were treated preemptively with cidofovir 1 mg/kg/day given three times weekly for three wk. A case-controlled study was performed to identify risk factors for high-risk ADV infections. Seven (18{\%}) of the 38 subjects developed high-risk ADV infections usually within 100 days of HPCT and were preemptively treated with i.v. cidofovir at a dose of 1 mg/kg/dose three times weekly for nine doses. High-risk ADV infections resolved in all seven patients without renal toxicity. CMV viremia occurred in two of seven patients during or shortly after therapy with cidofovir. A case-control study did not identify any risk factors that achieved statistical significance. Treatment with a modified dosing regimen of cidofovir was well-tolerated and high-risk ADV infections resolved in all patients.",
keywords = "Adenovirus, Cidofovir, Hematopoietic progenitor cell transplantation, Infection, Treatment",
author = "Anderson, {Evan J.} and Judith Guzman-Cottrill and Morris Kletzel and Kimberly Thormann and Christine Sullivan and Xiaotian Zheng and Katz, {Ben Z.}",
year = "2008",
month = "3",
doi = "10.1111/j.1399-3046.2007.00851.x",
language = "English (US)",
volume = "12",
pages = "219--227",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy

AU - Anderson, Evan J.

AU - Guzman-Cottrill, Judith

AU - Kletzel, Morris

AU - Thormann, Kimberly

AU - Sullivan, Christine

AU - Zheng, Xiaotian

AU - Katz, Ben Z.

PY - 2008/3

Y1 - 2008/3

N2 - ADV has emerged as an important pathogen in children undergoing allogeneic HPCT. A prospective study of the epidemiology of ADV infection and preemptive therapy of high risk ADV infections in children undergoing HPCT was undertaken. Cultures of throat, urine, and stool for viral pathogens and plasma for ADV PCR were obtained prior to transplantation, weekly for the first 100 days, and then monthly for one yr. Children developing high-risk ADV infections were treated preemptively with cidofovir 1 mg/kg/day given three times weekly for three wk. A case-controlled study was performed to identify risk factors for high-risk ADV infections. Seven (18%) of the 38 subjects developed high-risk ADV infections usually within 100 days of HPCT and were preemptively treated with i.v. cidofovir at a dose of 1 mg/kg/dose three times weekly for nine doses. High-risk ADV infections resolved in all seven patients without renal toxicity. CMV viremia occurred in two of seven patients during or shortly after therapy with cidofovir. A case-control study did not identify any risk factors that achieved statistical significance. Treatment with a modified dosing regimen of cidofovir was well-tolerated and high-risk ADV infections resolved in all patients.

AB - ADV has emerged as an important pathogen in children undergoing allogeneic HPCT. A prospective study of the epidemiology of ADV infection and preemptive therapy of high risk ADV infections in children undergoing HPCT was undertaken. Cultures of throat, urine, and stool for viral pathogens and plasma for ADV PCR were obtained prior to transplantation, weekly for the first 100 days, and then monthly for one yr. Children developing high-risk ADV infections were treated preemptively with cidofovir 1 mg/kg/day given three times weekly for three wk. A case-controlled study was performed to identify risk factors for high-risk ADV infections. Seven (18%) of the 38 subjects developed high-risk ADV infections usually within 100 days of HPCT and were preemptively treated with i.v. cidofovir at a dose of 1 mg/kg/dose three times weekly for nine doses. High-risk ADV infections resolved in all seven patients without renal toxicity. CMV viremia occurred in two of seven patients during or shortly after therapy with cidofovir. A case-control study did not identify any risk factors that achieved statistical significance. Treatment with a modified dosing regimen of cidofovir was well-tolerated and high-risk ADV infections resolved in all patients.

KW - Adenovirus

KW - Cidofovir

KW - Hematopoietic progenitor cell transplantation

KW - Infection

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=40149092008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40149092008&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2007.00851.x

DO - 10.1111/j.1399-3046.2007.00851.x

M3 - Article

VL - 12

SP - 219

EP - 227

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 2

ER -